An open-label, multicenter, mechanism validation study to evaluate the safety, efficacy and tolerability of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV-1-infected subjects.

Trial Profile

An open-label, multicenter, mechanism validation study to evaluate the safety, efficacy and tolerability of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV-1-infected subjects.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs KP 1461 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational
  • Sponsors Koronis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2011 Planned end date changed from 1 Dec 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Results published in the PLoS One Journal (January 14), according to a Koronis Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top